NCT07895459Recruiting
MRD Monitoring in Colorectal Cancer Using ctDNA
Monitoring of Minimal Residual Disease (MRD) in Selected Patients With Colorectal Cancer (Stages II-IV) Using Analysis of Circulating Tumor DNA (ctDNA) by the ddPCR Method
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This clinical study evaluates the use of free circulating tumor DNA (ctDNA) analysis from peripheral blood, known as liquid biopsy. The objective is to detect minimal residual disease (MRD) early and to predict disease relapse or progression in patients with colorectal cancer (stages II-IV). By monitoring specific KRAS gene mutations (G12 and G13) using the ddPCR method, the study aims to improve risk stratification and treatment response monitoring following primary therapy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 19 Oct 2026
- Start date
- Feb 2023
- Primary completion date
- Jan 2027
- Lead sponsor
- Masaryk Memorial Cancer Institute
- Diseases
- Colorectal cancer
- NCT number
- NCT07895459
What you commit to
- Study type: Interventional
- Planned participants: 60
- From Feb 2023 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active second primary malignancy that could interfere with ctDNA interpretation.
Other
- Absence of target KRAS mutations (G12/G13) in the primary tumor.
- Inability or unwillingness to comply with scheduled blood sampling and follow-up visits.
Who the study is looking for
- Histologically confirmed diagnosis of colorectal cancer (clinical stage II, III, or IV).
- Presence of KRAS gene mutation (specifically G12 or G13 mutations) confirmed in the primary tumor tissue.
- Age 18 years or older at the time of inclusion.
- Patient scheduled for standard primary surgical resection, local treatment, or adjuvant therapy as per institutional guidelines.
- Signed written informed consent to participate in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Masaryk Memorial Cancer Institute Coordinator of this site? Confirm its status | Brno | Czechia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.